This week on Capitol Hill, the heated drug pricing debate is back in the spotlight, with a Senate Judiciary Committee hearing on intellectual property and the price of prescription drugs on Tuesday. In the House of Representatives, oversight hearings will examine both the activities of the U.S. Patent and Trademark Office and data security efforts made by the Federal Trade Commission. Off the Hill, The Cato Institute looks at U.S. cyber defense capabilities, and the week closes with a Brookings Institution event on China’s actions towards global tech dominance.
Recent Posts
- CAFC: Jury Instructions Must Address Each Objective Indicia of Nonobviousness Raised by Patent Owner
- Massive Replication of Comments Submitted to NIST March-In Rights RFI Should Cause Concern
- Lourie Dissents from CAFC View that Heart Valve Transport was Not Infringing
- Rader’s Ruminations – Patent Eligibility II: How the Supreme Court Ignored Statute and Revived Its Innovation-Killing Two-Step
- Other Barks and Bites for Friday, March 22: French Watchdog Hits Google with €250 Million for IP Breaches; C4IP Releases First Congressional Innovation Scorecard; EPO Sees Record Number of Patent Applications